ブタクサ花粉過敏症の世界市場:パイプラインインサイト2021

【英語タイトル】Ragweed pollen hypersensitivity - Pipeline Insight, 2021

DelveInsightが出版した調査資料(DELV21SE031)・商品コード:DELV21SE031
・発行会社(調査会社):DelveInsight
・発行日:2021年9月
・ページ数:60
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:世界
・産業分野:グローバル
◆販売価格オプション(消費税別)
Single UserUSD1,500 ⇒換算¥222,000見積依頼/購入/質問フォーム
Global Site LicenseUSD4,500 ⇒換算¥666,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

DelveInsight’s, “Ragweed pollen hypersensitivity – Pipeline Insight, 2021,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Ragweed pollen hypersensitivity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
• Global coverage

Ragweed pollen hypersensitivity Understanding
Ragweed pollen hypersensitivity: Overview
While many people regard spring as prime pollen season, one type of pollen wreaks havoc in the late summer and fall. Ragweed pollen usually reaches peak levels in mid-September; this type of pollen can cause seasonal allergic rhinitis (more commonly known as hay fever), which affects as many as 23 million people in the U.S. Symptoms of ragweed allergy are similar to those of other pollen allergies: Sneezing, Runny nose, Nasal congestion, Headaches, Irritated eyes, Itchy throat. Ragweed pollen can also aggravate asthma symptoms, leading to increased coughing and wheezing. Ragweed allergies can be treated with antihistamines and other allergy medications.

“”Ragweed pollen hypersensitivity – Pipeline Insight, 2021″” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ragweed pollen hypersensitivity pipeline landscape is provided which includes the disease overview and Ragweed pollen hypersensitivity treatment guidelines. The assessment part of the report embraces, in depth Ragweed pollen hypersensitivity commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ragweed pollen hypersensitivity collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Ragweed pollen hypersensitivity R&D. The therapies under development are focused on novel approaches to treat/improve Ragweed pollen hypersensitivity.

Ragweed pollen hypersensitivity Emerging Drugs Chapters
This segment of the Ragweed pollen hypersensitivity report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ragweed pollen hypersensitivity Emerging Drugs
• Ragweed MATA MPL: Allergy Therapeutics
Allergy Therapeutics is developing an Antiallergic to treat Ragweed pollen hypersensitivity. The therapy is currently in Phase III stage of clinical trial evaluation.

• rag-ASIT+™: ASIT biotech
ASIT biotech is developing a therapy to treat Ragweed pollen hypersensitivity. The preclinical, clinical and production process of gp-ASIT+TM for the treatment of allergic rhinitis can be fully leveraged for the development of allergen fragments from other allergens such as house dust mite, ragweed and food allergens like peanut and eggwhite. The flexibility of the platform allows for adaption of the process to particular characteristics of a specific allergen.
Further product details are provided in the report……..

Ragweed pollen hypersensitivity: Therapeutic Assessment
This segment of the report provides insights about the different Ragweed pollen hypersensitivity drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Ragweed pollen hypersensitivity
There are approx. 2+ key companies which are developing the therapies for Ragweed pollen hypersensitivity. The companies which have their Ragweed pollen hypersensitivity drug candidates in the most advanced stage, i.e. phase III include, Allergy Therapeutics.

• Phases
DelveInsight’s report covers around 2+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Ragweed pollen hypersensitivity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ragweed pollen hypersensitivity: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ragweed pollen hypersensitivity therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ragweed pollen hypersensitivity drugs.

Ragweed pollen hypersensitivity Report Insights
• Ragweed pollen hypersensitivity Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Ragweed pollen hypersensitivity Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Ragweed pollen hypersensitivity drugs?
• How many Ragweed pollen hypersensitivity drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ragweed pollen hypersensitivity?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ragweed pollen hypersensitivity therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ragweed pollen hypersensitivity and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• HAL Allergy
• ASIT biotech
• Allergy Therapeutics
• Anergis

Key Products
• rag-ASIT+™
• Ragweed MATA MPL
• AllerDM

❖ レポートの目次 ❖

Introduction
Executive Summary
Ragweed pollen hypersensitivity: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Ragweed pollen hypersensitivity – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
• Comparative Analysis
Ragweed MATA MPL: Allergy Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
• Comparative Analysis
rag-ASIT+™: ASIT biotech
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Ragweed pollen hypersensitivity Key Companies
Ragweed pollen hypersensitivity Key Products
Ragweed pollen hypersensitivity- Unmet Needs
Ragweed pollen hypersensitivity- Market Drivers and Barriers
Ragweed pollen hypersensitivity- Future Perspectives and Conclusion
Ragweed pollen hypersensitivity Analyst Views
Ragweed pollen hypersensitivity Key Companies
Appendix



★調査レポート[ブタクサ花粉過敏症の世界市場:パイプラインインサイト2021] (コード:DELV21SE031)販売に関する免責事項を必ずご確認ください。
★調査レポート[ブタクサ花粉過敏症の世界市場:パイプラインインサイト2021]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆